DR.Bassem Mahmoud Hussein Al-Zoubi
Abstract: Management of Short Stature
Abstract :
Short stature is a frequent pediatric presentation that can signal a range of underlying physiological or pathological conditions. It is defined as a height more than two standard deviations below the mean for age and sex (i.e., below the 2.3rd percentile on standardized growth charts) [1].
A structured and systematic approach to evaluation is essential to distinguish between normal variants of growth—such as familial short stature and constitutional growth delay—and pathological causes, including endocrine disorders (e.g., growth hormone deficiency, hypothyroidism), chronic systemic illnesses (e.g., gastrointestinal, renal, or cardiac disease), genetic syndromes (e.g., Turner syndrome, Noonan syndrome), and nutritional deficiencies [2].
Initial evaluation begins with a detailed growth history, review of perinatal factors, family height data, and growth velocity over time. Accurate anthropometric measurements, plotted on WHO or CDC growth charts, are vital. Bone age assessment via left hand-wrist radiography provides insight into growth potential and pubertal development [3].
Further laboratory investigations should be guided by clinical suspicion and may include :
• Complete blood count and ESR to screen for chronic illness
• Thyroid function tests (TSH, free T4)
• Serum IGF-1 and IGFBP-3 as screening tools for growth hormone axis
• Karyotype (especially in girls with unexplained short stature to exclude Turner syndrome)
• Coeliac disease screening (tissue transglutaminase antibodies)
• Renal and liver function tests
In cases with suspected growth hormone deficiency, a growth hormone stimulation test remains the gold standard for diagnosis [4].
Management depends on the etiology:
• Nutritional and chronic disease-related short stature is addressed by treating the underlying condition.
• Endocrine disorders may require hormonal replacement therapy, such as levothyroxine for hypothyroidism or recombinant human growth hormone (rhGH) for GHD, Turner syndrome, chronic renal insufficiency, and other FDA-approved indications [5].
• Psychosocial support is essential to address the emotional impact of short stature and improve quality of life.
Early detection and timely intervention are critical to optimizing final adult height and psychosocial outcomes. Close follow-up by pediatric endocrinologists is recommended for all children with pathological short stature.
Key References:
1. Rogol AD, Hayden GF. “Etiologies and early diagnosis of short stature and growth failure in children and adolescents.” J Pediatr. 2014;164(5 Suppl):S1–S14. doi:10.1016/j.jpeds.2014.02.027
2. Allen DB, Cuttler L. “Short stature in childhood—Challenges and choices.” N Engl J Med. 2013;368(13):1220-1228. doi:10.1056/NEJMcp1210380
3. Kaplowitz P, et al. “Evaluation and referral of children with signs of early puberty or short stature: A pediatrician’s guide.” Pediatr Rev. 2016;37(7):259–271.
4. Grimberg A, et al. “Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: Growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency.” Horm Res Paediatr. 2016;86(6):361–397.
5. Cohen P, et al. “Consensus statement on the diagnosis and treatment of children with idiopathic short stature: A summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology.” J Clin Endocrinol Metab. 2008;93(11):4210–4217.